PharmaTimes Media Ltd reported that the FDA approved Tivicay for youngest HIV patients.
Public source
Publisher name
Public post
FDA approves Tivicay pd for youngest HIV patients https://lnkd.in/e2hhTUrA
Company
PharmaTimes Media Ltd
Kickstarting healthcare conversations.
- Industry
- Pharmaceutical Manufacturing
- Location
- Leatherhead, GB
- Company size
- 11–50 employees
About PharmaTimes Media Ltd
Kickstarting healthcare conversations. PharmaTimes Magazine is the leading pharmaceutical magazine for senior decision makers in the pharma and healthcare industries. It is recognised for its wide-ranging coverage of the key developments facing this fast-paced sector, and its analytical, independent content. PharmaTimes Magazine has a dedicated staff of writers and editors who have many years' experience in writing and editing copy for pharma and healthcare readers in national newspapers, magazines and online. PharmaTimes Magazine readers range from pharmaceutical executives, to healthcare professionals (chief pharmacists, medicines management, academic health science networks and NHS commissioners), to government ministers. Available in print and digital versions, on Newsstand and Google Play. PharmaTimes Competitions provide business partners and sponsors with unique access to senior decision makers, in order to gain real insight into the business challenges faced by pharma customers. This allows partners and sponsors the opportunity to build relationships and formulate service offerings around customer needs.
See moreLatest activity
Latest activity from PharmaTimes Media Ltd
4 signals
Legal & Regulatory
PharmaTimes Media Ltd reports that Heparegenix has won orphan drug status for darizmetinib
Research & Knowledge
PharmaTimes Media Ltd reported that the first patient in a Koala trial received doses of a novel KMA-targeting CAR-T therapy.
Partnerships
PharmaTimes Media Ltd announced that Nxera partner gains acceptance for NBI-1117567
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
PhRMA
PhRMA noted that in October 2025, the FDA approved a breakthrough treatment for pulmonary fibrosis, allowing patients in the United States to access it quickly.
Legal & Regulatory
UNAIDS
UNAIDS announced that countries around the world have committed to ensuring the global accessibility, availability, and affordability of HIV medicines, diagnostics, and other essential technologies.
Legal & Regulatory
RetroVirox Inc.
RetroVirox Inc. announced that the U.S. FDA approved Gilead's Bixlenvo for HIV treatment in virologically suppressed adults.
Legal & Regulatory
Steripharm Solutions LLC™
Steripharm Solutions LLC™ is reminding compounders not to use dietary activity.
Legal & Regulatory
Linical